home | publications


1. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer
McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP; Casodex Early Prostate Cancer Trialists' Group.
BJU Int. 2006 Feb;97(2):247-54.

2. Regulation of Apoptosis by a Prostate Specific and Prostate Cancer-Associated Non-coding Gene, PCGEM1
Xiaoqin Fu, Lakshmi Ravindranath, Nicholas Tran, Gyorgy Petrovics, Shiv Srivastava.
DNA Cell Biol. 2006 Mar;25(3):135-41

3. Preferential radiation sensitization of prostate cancer in nude mice by nutraceutical antioxidant gamma-tocotrienol
Kumar KS, Raghavan M, Hieber K, Ege C, Mog S, Parra N, Hildabrand A, Singh V, Srinivasan V, Toles R, Karikari P, Petrovics G, Seed T, Srivastava S, Papas A.
Life Sci. 2006 Mar 27;78(18):2099-104. Epub 2006 Jan 18

4. Phenotypic Characterization of telomerase-immortalizes primary non-malignant and malignant tumor-derived human prostate epithelial cell lines
Yongpeng Gu, Hongzhen Li, Jun Miki, Kee-Hong Kim, Bungo Furusato, Isabell A. Sesterhenn, Wei-Sing Chu, David G. McLeod, Shiv Srivastava, Charles M. Ewing, William B. Isaacs, and Johng S. Rhim.
Exp Cell Res. 2006 Apr 1;312(6):831-43. Epub 2006 Jan 17

5. Prostate Cancer Associated Androgen Receptor Mutation (T877A) Promotes Cell Growth and Abrogates p53 Mediated Apoptosis
Sun C, Shi Y, Xu LL, Nageswararao C, Davis LD, Segawa T, Dobi AL, McLeod DG, Moul JW, Srivastava S.
Oncogene. 2006 Jun 29;25(28):3905-13. Epub 2006 Apr 24

6. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup
McLeod DG, See WA, Klimberg I, Gleason D, Chodak G, Montie J, Bernstein G, Morris C, Armstrong J.
J Urol. 2006 Jul;176(1):75-80

7. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality
Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D'Amico AV.
Urology. 2006 Aug;68(2):342-7

8. Quantitative expression profile of PSGR in prostate cancer
Xu LL, Sun C, Petrovics G, Makarem M, Furusato B, Zhang W, Sesterhenn IA, McLeod DG, Sun L, Moul JW, Srivastava S.
Prostate Cancer Prostatic Dis. 2006;9(1):56-61

9. Distinct Effects of Annexin A7 and p53 on Arachidonate Lipoxygenation in Prostate Cancer Cells Involve 5-Lipoxygenase Transcription
Torosyan Y, Dobi A, Naga S, Mezhevaya K, Glasman M, Norris C, Jiang G, Mueller G, Pollard H, Srivastava M.
Cancer Res. 2006 Oct 1;66(19):9609-16

10. The emergence of radioimmunoscintigraphy for prostate cancer
Keane TE, Rosner IL, Wingo MS, McLeod DG
Rev Urol. 2006;8 Suppl 1:S20-8

11. Androgen Receptor and Prostate Cancer (Review)
Eric Richter, Shiv Srivastava and Albert Dobi
Prostate Cancer Prostatic Dis. 2006

12. Characterization of frequently deleted 6q locus in prostate cancer
Sun M, Srikantan V, Ma L, Li J, Zhang W, Petrovics G, Makarem M, Strovel JW, Horrigan SG, Augustus M, Sesterhenn IA, Moul JW, Chandrasekharappa S, Zou Z, Srivastava S
DNA Cell Biol. 2006 Nov;25(11):597-607

13. Time to an Undetectable PSA Following Androgen Suppression Therapy for Post-operative or Post-radiation PSA Recurrence and Prostate Cancer-Specific Mortality
D'Amico A, Chen MH, McLeod DG, Cullen, J, Carroll P.
Cancer, 2007